Clinical Trial Update: Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Lunsekimig versus placebo in adults with eosinophilic chronic obstructive pulmonary disease is currently recruiting to assess …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Lunsekimig (Lunsekimig)

Snippet

Sponsor: Sanofi | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: RECRUITING